ClinicalTrials.gg
RecruitingNCT07497607REDUCE-30Updated May 18, 2026

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

A Phase 2 interventional study of Cisplatin and Radiotherapy in Oropharyngeal Squamous Cell Carcinoma and HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by Sara Medek. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Sara Medek · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck — 19 open to participants now, 31 under way, 5 of them phase 3. Cisplatin · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
71st of 107
31 · median 47
Started
2026
with 6 others
Phase 2
70 of 115
18 open now
Primary completion
2031-05
later than 28 of 30 live
Registered
111th of 115
by date

Among the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck, this one is the 71st largest by planned enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2026, is one of 70 in phase 2, reaches primary completion later than 28 of the 30 other live ones, and was the 111th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

19 of the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.

Read the detailed description

The purpose of this research is to determine if a decrease in the dose of radiation to regions which have no visible cancer will be as effective as the standard dose. The dose to all visible cancer remains unchanged to the standard radiation approach. The researchers believe that a lower dose could be just as helpful for treatment, while reducing the side effects of radiation and improving quality of life.

The current standard care treatment for OPSCC can have debilitating side effects. Using a decreased dose of 30 Gy from 46-54 Gy to regions without visible cancer but which have a risk of microscopic cancer might be just as effective for treating cancer with less side effects. The combination of these approaches is not considered the current standard of care. Patients will continue to receive standard systemic therapy of cisplatin during radiation therapy.

03

Conditions studied

  • Oropharyngeal Squamous Cell Carcinoma
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have or cytologically confirmed history of squamous cell carcinoma of the oropharynx (OPSCC) planned for definitive chemoradiation.
  2. Squamous cell carcinoma of the oropharynx (OPSCC) must be confirmed to be p16 positive based on immunohistochemical staining.
  3. OPSCC must be clinical stage T1-4N1-3M0 or T3-T4N0M0 as per AJCC volume 8.
  4. Patients must have based on PET/CT imaging completed within 45 days +/- 1 week from date of eligibility confirmation.
  5. Age ≥18 years.
  6. performance status ≤2.
  7. Patients must be deemed eligible for planned SOC cisplatin per treating investigators and/or treating medical oncologist.
  8. Women of and men must agree to use adequate (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  9. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with or recurrent disease.

    2. Carcinoma of the neck of unknown primary site origin (T0 is ineligible even if p16 is positive).

    3. Prior radiotherapy resulting in overlap of radiation therapy fields.

    4. Patients who are pregnant, nursing or intended to conceive or father children during the course of the study.

    5. Patients with active or connective tissue disease that require systemic treatment in the opinion of the Investigator.

    6. Patients who are receiving any other agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the Investigator.

    7. Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous or not preferable, in the opinion of the Investigator.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Reduced Elective Nodal and CTV Dose

    Reduction in primary tumor and nodal CTV dose to 30 Gy.

    Drug: Cisplatin · Radiation: Radiotherapy

Interventions

  • Subjects will continue to receive standard systemic therapy of cisplatin during radiation therapy. Weekly SOC Cisplatin at a dose of 40mg/m2 or every 3-week dosing of 100mg/m2 will be administered per institutional guidelines during radiation therapy. The first cisplatin infusion should be initiated during the window from 24 hours before, to 48 hours after the first scheduled radiation treatment. Skipped cisplatin infusions should not be made up, and the last cisplatin infusion should be no later than 7 days after the last fraction of radiation.

  • RadiationRadiotherapy

    Radiotherapy will involve a sequential boost approach. Treatment will begin with coverage of the primary site and elective nodal regions to 30 Gy, after which treatment volumes will be reduced to primary site and involved nodes only with PTV margin to 70 Gy.

06

What researchers measure

Primary outcomes

  1. Change in dose and volume to all clinical target volumes (CTV) via Progression-Free Survival (PFS)

    To evaluate the efficacy of a reduction in dose and volume to all clinical target volumes (CTV) in patients with HPV-positive squamous cell carcinoma of the oropharynx (OPSCC) using 2-year Progression-Free Survival (PFS). Efficacy will be determined by the PFS rate at 2 years post-treatment, through continuous assessment with a boundary of 10% progression at 2 years (90% 2 year PFS).

    Time frame: 2 years post treatment

Secondary outcomes

  1. Safety evaluated per CTCAE v6

    To evaluate safety by collecting adverse events per CTCAE v6 in patients who have HPV positive SCC of the oropharynx using a reduction in primary tumor and nodal CTV dose to 30 Gy.

    Time frame: Adverse events collected through 30 days post treatment and SAEs through 90 days post-treatment or until commencement of new anti-cancer therapy, whichever occurs first.

  2. Quality of life measured by MDADI

    The MDADI is a patient-reported outcome (PRO) instrument designed to assess swallowing-related quality of life in patients with head and neck cancer and dysphagia. It evaluates the functional, emotional, and physical impact of swallowing difficulties on daily life. The scale ranges from 20 - 100. Higher scores indicate better swallowing function and better swallowing-related quality of life. Lower scores indicate worse dysphagia-related quality of life To assess the impacts on quality of life on patients who have HPV positive SCC of the oropharynx who receive a reduction in CTV dose to 30 Gy as well as a reduction in CTV volumes, via the EORTC QLQ-C30 at baseline, week 7/EOT, 6 months, 12 months 18 months and 24 months following completion of radiation therapy.

    Time frame: Baseline, at time of treatment completion, at 6-month intervals following treatment until 2 years after completion of RT

  3. Quality of life measured by EORTC QLQ-C30

    European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire-Core 30. t is a validated patient-reported outcome (PRO) instrument designed to assess health-related quality of life (HRQoL) in patients with cancer across clinical trials and routine practice. The transformed scale ranges from 0 - 100. Functional and Global Health scales: higher = better Symptom scales/items: higher = worse To assess the impacts on quality of life on patients who have HPV positive SCC of the oropharynx who receive a reduction in CTV dose to 30 Gy as well as a reduction in CTV volumes, via the EORTC QLQ-C30 at baseline, week 7/EOT, 6 months, 12 months 18 months and 24 months following completion of radiation therapy.

    Time frame: Baseline, at time of treatment completion, at 6-month intervals following treatment until 2 years after completion of RT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2031, 60 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 60 months is close to that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartActual
May 13, 2026
Primary completionEst.
May 13, 2031
CompletionEst.
May 13, 2036
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07497607
Lead sponsor
Sara Medek
Responsible party
Sara Medek (Principal Investigator, University of Cincinnati) — Sponsor-investigator
First posted
Mar 27, 2026
Start date
May 13, 2026
Primary completion
May 13, 2031 (estimated)
Completion
May 13, 2036 (estimated)
Last update
May 18, 2026

Study contacts

UCCC Clinical Trials Office
Contact
cancer@uchealth.com
513-584-7698
Sara Medek, MD
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin

Start the discussion